Loading...
Keywords
Last Name
Institution
 Back to Details

Connection

J. Steven Leeder to Genotype

This is a "connection" page, showing publications J. Steven Leeder has written about Genotype.

 
Connection Strength
  
 
 
3.700
  
  1. Wagner JB, Abdel-Rahman S, Raghuveer G, Gaedigk A, Boone EC, Gaedigk R, Staggs VS, Reed GA, Zhang N, Leeder JS. SLCO1B1 Genetic Variation Influence on Atorvastatin Systemic Exposure in Pediatric Hypercholesterolemia. Genes (Basel). 2024 Jan 15; 15(1).
    View in: PubMed
    Score: 0.217
  2. Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, Gaedigk A, Klein TE, Caudle KE, McCracken JT, de Leon J, Leeder JS. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clin Pharmacol Ther. 2019 07; 106(1):94-102.
    View in: PubMed
    Score: 0.156
  3. Bhatt DK, Mehrotra A, Gaedigk A, Chapa R, Basit A, Zhang H, Choudhari P, Boberg M, Pearce RE, Gaedigk R, Broeckel U, Leeder JS, Prasad B. Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver. Clin Pharmacol Ther. 2019 01; 105(1):131-141.
    View in: PubMed
    Score: 0.148
  4. Wagner JB, Abdel-Rahman S, Van Haandel L, Gaedigk A, Gaedigk R, Raghuveer G, Kauffman R, Leeder JS. Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. J Clin Pharmacol. 2018 06; 58(6):823-833.
    View in: PubMed
    Score: 0.145
  5. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017 01; 19(1):69-76.
    View in: PubMed
    Score: 0.129
  6. Dinh JC, Pearce RE, Van Haandel L, Gaedigk A, Leeder JS. Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children. Drug Metab Dispos. 2016 07; 44(7):1070-9.
    View in: PubMed
    Score: 0.127
  7. Brown JT, Abdel-Rahman SM, van Haandel L, Gaedigk A, Lin YS, Leeder JS. Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. Clin Pharmacol Ther. 2016 06; 99(6):642-50.
    View in: PubMed
    Score: 0.125
  8. Vyhlidal CA, Pearce RE, Gaedigk R, Calamia JC, Shuster DL, Thummel KE, Leeder JS. Variability in Expression of CYP3A5 in Human Fetal Liver. Drug Metab Dispos. 2015 Aug; 43(8):1286-93.
    View in: PubMed
    Score: 0.119
  9. Gaedigk A, Freeman N, Hartshorne T, Riffel AK, Irwin D, Bishop JR, Stein MA, Newcorn JH, Jaime LK, Cherner M, Leeder JS. SNP genotyping using TaqMan technology: the CYP2D6*17 assay conundrum. Sci Rep. 2015 Mar 19; 5:9257.
    View in: PubMed
    Score: 0.118
  10. Leeder JS, Brown JT, Soden SE. Individualizing the use of medications in children: making Goldilocks happy. Clin Pharmacol Ther. 2014 Sep; 96(3):304-6.
    View in: PubMed
    Score: 0.112
  11. Leeder JS, Gaedigk A. CYP2D6 and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects. Pharmacogenomics. 2014 Jun; 15(8):1055-8.
    View in: PubMed
    Score: 0.112
  12. Goldman J, Becker ML, Jones B, Clements M, Leeder JS. Development of biomarkers to optimize pediatric patient management: what makes children different? Biomark Med. 2011 Dec; 5(6):781-94.
    View in: PubMed
    Score: 0.094
  13. Gaedigk A, Twist GP, Leeder JS. CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR. Pharmacogenomics. 2012 Jan; 13(1):91-111.
    View in: PubMed
    Score: 0.094
  14. Becker ML, Gaedigk R, van Haandel L, Thomas B, Lasky A, Hoeltzel M, Dai H, Stobaugh J, Leeder JS. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum. 2011 Jan; 63(1):276-85.
    View in: PubMed
    Score: 0.088
  15. Becker ML, Leeder JS. Identifying genomic and developmental causes of adverse drug reactions in children. Pharmacogenomics. 2010 Nov; 11(11):1591-602.
    View in: PubMed
    Score: 0.087
  16. Gaedigk A, Fuhr U, Johnson C, B?rard LA, Bradford D, Leeder JS. CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics. 2010 Jan; 11(1):43-53.
    View in: PubMed
    Score: 0.082
  17. Leeder JS, Pearce RE, Gaedigk A, Modak A, Rosen DI. Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype. J Clin Pharmacol. 2008 Sep; 48(9):1041-51.
    View in: PubMed
    Score: 0.075
  18. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008 Feb; 83(2):234-42.
    View in: PubMed
    Score: 0.071
  19. Blake MJ, Gaedigk A, Pearce RE, Bomgaars LR, Christensen ML, Stowe C, James LP, Wilson JT, Kearns GL, Leeder JS. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther. 2007 Apr; 81(4):510-6.
    View in: PubMed
    Score: 0.067
  20. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006 Aug 19; 368(9536):704.
    View in: PubMed
    Score: 0.065
  21. Gaedigk A, Baker DW, Totah RA, Gaedigk R, Pearce RE, Vyhlidal CA, Zeldin DC, Leeder JS. Variability of CYP2J2 expression in human fetal tissues. J Pharmacol Exp Ther. 2006 Nov; 319(2):523-32.
    View in: PubMed
    Score: 0.065
  22. Gaedigk A, Leeder JS. Comments on Hoskins et al. [(2005) drug metab dispos 33:1564-1565]. Drug Metab Dispos. 2006 Mar; 34(3):504-5; author reply 506.
    View in: PubMed
    Score: 0.063
  23. Gaedigk A, Bradford LD, Alander SW, Leeder JS. CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab Dispos. 2006 Apr; 34(4):563-9.
    View in: PubMed
    Score: 0.062
  24. Gaedigk A, Gaedigk R, Leeder JS. CYP2D7 splice variants in human liver and brain: does CYP2D7 encode functional protein? Biochem Biophys Res Commun. 2005 Nov 04; 336(4):1241-50.
    View in: PubMed
    Score: 0.062
  25. Leeder JS, Gaedigk R, Marcucci KA, Gaedigk A, Vyhlidal CA, Schindel BP, Pearce RE. Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther. 2005 Aug; 314(2):626-35.
    View in: PubMed
    Score: 0.059
  26. Gaedigk A, Bhathena A, Ndjountch? L, Pearce RE, Abdel-Rahman SM, Alander SW, Bradford LD, Rogan PK, Leeder JS. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J. 2005; 5(3):173-82.
    View in: PubMed
    Score: 0.058
  27. Kennedy MJ, Abdel-Rahman SM, Kashuba AD, Leeder JS. Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children. J Clin Pharmacol. 2004 Jul; 44(7):708-14.
    View in: PubMed
    Score: 0.056
  28. Gaedigk A, Ryder DL, Bradford LD, Leeder JS. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin Chem. 2003 Jun; 49(6 Pt 1):1008-11.
    View in: PubMed
    Score: 0.052
  29. Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, Singh AB, Rua?o G, Mueller DJ, Tsermpini EE, Brown JT, Bell GC, Leeder JS, Gaedigk A, Scott SA, Klein TE, Caudle KE, Bishop JR. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023 07; 114(1):51-68.
    View in: PubMed
    Score: 0.052
  30. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther. 2002 Jul; 72(1):76-89.
    View in: PubMed
    Score: 0.049
  31. Dinh JC, Boone EC, Staggs VS, Pearce RE, Wang WY, Gaedigk R, Leeder JS, Gaedigk A. The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity. Clin Pharmacol Ther. 2022 03; 111(3):646-654.
    View in: PubMed
    Score: 0.047
  32. Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol. 2001 Oct; 79(10):841-7.
    View in: PubMed
    Score: 0.046
  33. Hertz DL, Ramsey LB, Gopalakrishnan M, Leeder JS, Van Driest SL. Analysis Approaches to Identify Pharmacogenetic Associations With Pharmacodynamics. Clin Pharmacol Ther. 2021 09; 110(3):589-594.
    View in: PubMed
    Score: 0.046
  34. Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, Dunnenberger HM, Leeder JS, Callaghan JT, Samer CF, Klein TE, Haidar CE, Van Driest SL, Ruano G, Sangkuhl K, Cavallari LH, M?ller DJ, Prows CA, Nagy M, Somogyi AA, Skaar TC. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021 10; 110(4):888-896.
    View in: PubMed
    Score: 0.044
  35. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics. 1999 Dec; 9(6):669-82.
    View in: PubMed
    Score: 0.041
  36. Ogungbenro K, Wagner JB, Abdel-Rahman S, Leeder JS, Galetin A. A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents. Eur J Clin Pharmacol. 2019 Sep; 75(9):1227-1235.
    View in: PubMed
    Score: 0.040
  37. Shakhnovich V, Abdel-Rahman S, Friesen CA, Weigel J, Pearce RE, Gaedigk A, Leeder JS, Kearns GL. Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity. Pediatr Obes. 2019 01; 14(1).
    View in: PubMed
    Score: 0.038
  38. Gaedigk A, Tyndale RF, Jurima-Romet M, Sellers EM, Grant DM, Leeder JS. NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics. 1998 Aug; 8(4):305-13.
    View in: PubMed
    Score: 0.037
  39. Bhatt DK, Basit A, Zhang H, Gaedigk A, Lee SB, Claw KG, Mehrotra A, Chaudhry AS, Pearce RE, Gaedigk R, Broeckel U, Thornton TA, Nickerson DA, Schuetz EG, Amory JK, Leeder JS, Prasad B. Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex. Drug Metab Dispos. 2018 06; 46(6):888-896.
    View in: PubMed
    Score: 0.036
  40. Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia. 1998; 39 Suppl 7:S8-16.
    View in: PubMed
    Score: 0.036
  41. Xu M, Bhatt DK, Yeung CK, Claw KG, Chaudhry AS, Gaedigk A, Pearce RE, Broeckel U, Gaedigk R, Nickerson DA, Schuetz E, Rettie AE, Leeder JS, Thummel KE, Prasad B. Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver. J Pharmacol Exp Ther. 2017 11; 363(2):265-274.
    View in: PubMed
    Score: 0.035
  42. Gaedigk A, Ndjountch? L, Divakaran K, Dianne Bradford L, Zineh I, Oberlander TF, Brousseau DC, McCarver DG, Johnson JA, Alander SW, Wayne Riggs K, Steven Leeder J. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther. 2007 Feb; 81(2):242-51.
    View in: PubMed
    Score: 0.034
  43. Prasad B, Gaedigk A, Vrana M, Gaedigk R, Leeder JS, Salphati L, Chu X, Xiao G, Hop C, Evers R, Gan L, Unadkat JD. Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics. Clin Pharmacol Ther. 2016 10; 100(4):362-70.
    View in: PubMed
    Score: 0.033
  44. Hicks JK, Bishop JR, Sangkuhl K, M?ller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015 Aug; 98(2):127-34.
    View in: PubMed
    Score: 0.030
  45. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ, Leeder JS, van Schaik R, Thummel KE, Klein TE, Caudle KE, MacPhee IA. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015 Jul; 98(1):19-24.
    View in: PubMed
    Score: 0.030
  46. Lalan S, Abdel-Rahman S, Gaedigk A, Leeder JS, Warady BA, Dai H, Blowey D. Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population. Pediatr Nephrol. 2014 Oct; 29(10):2039-49.
    View in: PubMed
    Score: 0.028
  47. Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatr Blood Cancer. 2014 Jun; 61(6):1055-62.
    View in: PubMed
    Score: 0.027
  48. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, Skaar TC. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014 Apr; 95(4):376-82.
    View in: PubMed
    Score: 0.027
  49. Wang D, Poi MJ, Sun X, Gaedigk A, Leeder JS, Sadee W. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet. 2014 Jan 01; 23(1):268-78.
    View in: PubMed
    Score: 0.026
  50. Twist GP, Gaedigk R, Leeder JS, Gaedigk A. High-resolution melt analysis to detect sequence variations in highly homologous gene regions: application to CYP2B6. Pharmacogenomics. 2013 Jun; 14(8):913-22.
    View in: PubMed
    Score: 0.026
  51. Feng Q, Kalari K, Fridley BL, Jenkins G, Ji Y, Abo R, Hebbring S, Zhang J, Nye MD, Leeder JS, Weinshilboum RM. Betaine-homocysteine methyltransferase: human liver genotype-phenotype correlation. Mol Genet Metab. 2011 Feb; 102(2):126-33.
    View in: PubMed
    Score: 0.022
  52. Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab Dispos. 2010 Jun; 38(6):894-7.
    View in: PubMed
    Score: 0.021
  53. Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, Koren G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther. 2009 Jan; 85(1):31-5.
    View in: PubMed
    Score: 0.019
  54. Gaedigk A, Eklund JD, Pearce RE, Leeder JS, Alander SW, Phillips MS, Bradford LD, Kennedy MJ. Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotype. Clin Pharmacol Ther. 2007 Jun; 81(6):817-20.
    View in: PubMed
    Score: 0.017
  55. Shelepova T, Nafziger AN, Victory J, Kashuba AD, Rowland E, Zhang Y, Sellers E, Kearns G, Leeder JS, Gaedigk A, Bertino JS. Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol. 2005 Dec; 45(12):1413-21.
    View in: PubMed
    Score: 0.015
  56. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther. 2004 Dec; 76(6):536-44.
    View in: PubMed
    Score: 0.014
  57. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther. 2003 Nov; 74(5):437-47.
    View in: PubMed
    Score: 0.013
  58. Gaedigk A, Ndjountch? L, Gaedigk R, Leeder JS, Bradford LD. Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D642, in African American subjects. Clin Pharmacol Ther. 2003 Jun; 73(6):575-6.
    View in: PubMed
    Score: 0.013
  59. Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther. 2000 Oct; 68(4):375-83.
    View in: PubMed
    Score: 0.011
  60. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Gaedigk A, Bertino JS. Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity. Pharmacogenetics. 1999 Aug; 9(4):453-62.
    View in: PubMed
    Score: 0.010
  61. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Shirey CS, Gotschall R, Gaedigk A, Bertino JS. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics. 1998 Oct; 8(5):403-10.
    View in: PubMed
    Score: 0.009
  62. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML, Kulawy RW, Beck DJ, Bertino JS. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther. 1998 Sep; 64(3):257-68.
    View in: PubMed
    Score: 0.009
  63. Henne KR, Gaedigk A, Gupta G, Leeder JS, Rettie AE. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J Chromatogr B Biomed Sci Appl. 1998 Jun 12; 710(1-2):143-8.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.